Autologous HSCT within six weeks prior to start of AMG 673 treatment.
Allogeneic HSCT within three months prior to start of AMG 673 treatment.
Prior HDT with autologous HSCT
Autologous HSCT within six weeks prior to start of AMG 330 treatment
Allogeneic HSCT within three months prior to start of AMG 330 treatment
Patients with aggressive NHL must have failed autologous hematopoietic stem cell transplantation (HSCT), or are ineligible or not consenting to autologous HSCT
Alemtuzumab treatment within 8 weeks of HSCT admission
Hodgkin lymphoma\r\n* Primary treatment failure ineligible for autologous HSCT\r\n* Relapse/progression after autologous HSCT
Relapsed post-autologous HSCT
Has received autologous HSCT within 6 weeks prior to start of treatment. Other Exclusion Criteria May Apply.
Alemtuzumab treatment within 8 weeks of HSCT admission
Hodgkin’s lymphoma\r\n* Primary treatment failure ineligible for autologous HSCT; relapse/progression after autologous HSCT
Treatment plan including autologous HSCT
Any previous autologous HSCT must have occurred at least 3 months prior to start of conditioning